From the Laboratoire Canaux Ioniques et Signalisation, CEA/DBMS, 17 rue des Martyrs, 38054 Grenoble, France, Istituto di
Cibernetica e Biofisica, CNR, Via de Marini 6, 16149 Genova, Italy, and
¶ Laboratoire Chimie des Protéines, CEA/DBMS, 17 rue des
Martyrs, 38054 Grenoble, France
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Triadin has been shown to co-localize with the
ryanodine receptor in the sarcoplasmic reticulum membrane. We show that
immunoprecipitation of solubilized sarcoplasmic reticulum membrane with
antibodies directed against triadin or ryanodine receptor, leads to the
co-immunoprecipitation of ryanodine receptor and triadin. We then
investigated the functional importance of the cytoplasmic domain of
triadin (residues 1-47) in the control of Ca2+
release from sarcoplasmic reticulum. We show that antibodies directed
against a synthetic peptide encompassing residues 2-17, induce a
decrease in the rate of Ca2+ release from sarcoplasmic
reticulum vesicles as well as a decrease in the open probability of the
ryanodine receptor Ca2+ channel incorporated in lipid
bilayers. Using surface plasmon resonance spectroscopy, we defined a
discrete domain (residues 18-46) of the cytoplasmic part of triadin
interacting with the purified ryanodine receptor. This interaction is
optimal at low Ca2+ concentration (up to pCa 5)
and inhibited by increasing calcium concentration (IC50 of
300 µM). The direct molecular interaction of this triadin
domain with the ryanodine receptor was confirmed by overlay assay and
shown to induce the inhibition of the Ca2+ channel activity
of purified RyR in bilayer. We propose that this interaction plays a
critical role in the control, by triadin, of the Ca2+
channel behavior of the ryanodine receptor and therefore may represent
an important step in the regulation process of excitation-contraction coupling in skeletal muscle.
In skeletal muscle cell, plasma membrane depolarization leads to
the release of calcium from the sarcoplasmic reticulum
(SR)1 (1). This process,
named excitation-contraction coupling, takes place in a specific region
of the cell where SR membrane faces the plasma membrane to form the
triad. Two proteins are mainly involved in this process (2). The
dihydropyridines receptor (DHPR) is localized in the plasma membrane
and senses its depolarization (3-5); the ryanodine receptor (RyR),
localized in the SR membrane, represents the exit way for
Ca2+ of the SR (6-8) (for review see Ref. 9). In
vivo, RyR opening is thought to be triggered by a charge movement
induced conformational change of the DHPR (10, 11). This "mechanical
coupling" hypothesis is supported by a number of results showing the
existence of a complex involving both RyR and DHPR (12-14). In
vitro, Ca2+ release from SR has been shown to be
modulated by a number of effectors such as ATP, Mg2+,
caffeine, ryanodine, and Ca2+ itself (8, 15-17).
Moreover, during recent years an increasing number of proteins located
in the triad have been shown to be able to regulate Ca2+
release from SR. Some of these proteins, such as the FK506-binding protein (FKBP12) and the cytoplasmic Ca2+-binding proteins
calmodulin and S100A1, interact directly with the RyR and modulate its
Ca2+ channel behavior (18-22). A different set of results
indicates that Ca2+ efflux through the RyR Ca2+
channel is also controlled by luminal Ca2+ concentration
presumably via a functional interaction between RyR and calsequestrin,
the major Ca2+-binding protein of the SR lumen (23,
24).
Different groups have proposed that another protein named triadin is
involved in the regulation of Ca2+ release from SR. Triadin
is of particular interest because it is one of the SR membrane proteins
that co-localize with RyR (26, 27). Skeletal triadin is a 95-kDa
glycoprotein (26, 28). Based on its primary sequence analysis and
accessibility to specific antibodies and protease, a model has been
proposed for the membrane topography of skeletal triadin in the SR
membrane (28, 29). This model shows that triadin is composed of a small
cytoplasmic region (amino acid 1-47), followed by a single
transmembrane domain and a large luminal region. Although different
results have suggested an interaction of triadin with either RyR, DHPR
, or calsequestrin (30-33), the exact role of triadin in the control
of the excitation-contraction coupling mechanism as well as the exact
domains of triadin involved in an interaction with RyR, have still to
be determined.
In this study, we investigated the functional interaction between the
cytoplasmic domain of triadin and the RyR. We show that antibodies
specifically directed against the N-terminal cytoplasmic extremity of
triadin inhibit caffeine-induced Ca2+ release from SR
vesicles by reducing the open probability of the RyR Ca2+
channel. Surface plasmon resonance measurements revealed a specific interaction of the cytoplasmic portion of triadin with purified RyR.
This was confirmed by overlay assays, which showed this interaction to
be direct. This interaction is dependent on the free Ca2+
concentration and is completely inhibited in the presence of several
millimolar of CaCl2. These results represent the first identification of a discrete domain of triadin directly involved in a
functional interaction with RyR. This interaction would allow a direct
control of RyR Ca2+ channel behavior by triadin from the
cytosolic side and therefore strongly suggests that triadin is a major
actor of excitation-contraction coupling in vivo.
Membrane Preparation--
Heavy sarcoplasmic reticulum (HSR)
vesicles were prepared from rabbit skeletal muscle as described
previously (14).
RyR Purification--
Ryanodine receptor was purified on sucrose
gradient after solubilization of HSR membrane with CHAPS as described
by Lai et al. (8). The fractions corresponding to the peak
of bound [3H]ryanodine were pooled and concentrated by
filtration on a YM30 membrane (Amicon Corp).
Synthetic Peptides--
Two peptides corresponding to residues
2-17 (peptide 1) and 18-46 (peptide 2) of the skeletal triadin (28)
were synthesized with an exogenous C-terminal Tyr and Cys,
respectively. A third peptide (peptide 3), not related to triadin, was
used for the surface plasmon resonance control experiments of
RyR-peptide 2 interaction. This peptide was chosen because of its
isoelectric point (pI 9.13) and molecular mass (2035 Da), which were
similar to those of peptide 2 (pI 8.98, molecular mass 3180,9 Da). For overlay assays, peptide 2 was synthesized with an exogenous C-terminal biotinylated Lys.
Antipeptides Antibodies--
Antibodies directed against
synthetic peptides corresponding to amino acids 2-17 (A-Nter) or
691-706 (A-Cter) extremity of triadin were obtained and characterized
as described previously (29). These antibodies were affinity purified
against the corresponding peptide. Fab fragments of affinity purified
A-Nter antibodies were prepared using a Fab preparation kit (Pierce).
Immunoprecipitation--
Heavy SR vesicles were solubilized in
the presence of CHAPS as described in Ref. 14. Solubilized proteins
were then incubated with antibodies specifically directed against
ryanodine receptor (anti-RyR) or either N-terminal (A-Nter) or
C-terminal (A-Cter) extremity of triadin. The immune complex was then
precipitated with protein A-Sepharose, and the immunoprecipitated
proteins identified by Western blot analysis using a chemiluminescent
technique after electrophoretic separation and transferred to an
Immobilon sheet. A-Nter and A-Cter antibodies as well as anti-RyR
antibodies used in these experiments were previously described by Marty
et al. (29).
Ca2+ Flux Measurements--
HSR vesicles (10 mg/ml)
were incubated for 14 h in ice in the presence or in the absence
of A-Nter antibodies (HSR protein/Ab ratio of 10 or 20). For control
experiments, A-Nter antibodies were preincubated with an excess of
corresponding peptide before their incubation with HSR vesicles.
Ca2+ uptake and Ca2+ release were then
monitored using arsenazo III as a Ca2+ indicator as
described previously (16). The arsenazo III signal was converted to
nanomoles of Ca2+ by determining the
For active Ca2+ loading of HSR vesicles, the vesicles (0.25 mg/ml) were incubated in a solution containing, 0.15 M KCl,
5.0 mM phosphoenolpyruvate, 10 units/ml pyruvate kinase, 2 mM MgCl2, 12.5 µM
CaCl2, 34 µM arsenazo III and 20 mM MES, pH 6.8 (solution A). After incubation for 15 min at
room temperature, Ca2+ uptake was induced by addition of 1 mM ATP.
For Ca2+ release experiments, HSR vesicles were actively
loaded as described above, and then mixed with 1 volume of solution B
containing 0.15 M KCl, 34 µM arsenazo III, 10 mM caffeine, and 20 mM MES, pH 6.8. The time
course of HSR Ca2+-release was monitored using a stopped
flow apparatus (Bio-Logic SFM-3). Ten to fifteen traces, each
representing 4,000 data points of the arsenazo III signal, were
averaged for each experiment.
RyR Ca2+ Channel Reconstitution and Single Channel
Recording Analysis--
Lipids bilayers were cast from a phospholipid
solution in n-decane containing a 5:2:3 mixture of
phosphatidylethanolamine/phosphatidylserine/phosphatidylcholine (30 mg/ml). The voltage control side was the cis chamber, and the trans chamber was referred to as ground. HSR membrane
vesicles or purified RyR were applied on top of the preformed bilayer
from the cis side. The experimental solutions were as
follows: for the cis chamber, 10 mM HEPES, pH
7.0, 250 mM NaCl, 1 mM ATP, 0.1 mM
CaCl2, 0.1 mM EGTA (pCa 5.5); and
for the trans chamber, 10 mM HEPES, pH 7.0, 50 mM NaCl, 0.1 mM CaCl2, 0.1 mM EGTA (pCa 5.5). Traces were recorded at 0 mV.
Single channel recording and analysis were performed as described
previously (21).
Real Time Surface Plasmon Resonance Recording--
Real time
surface plasmon resonance experiments were performed on a BIAcore
biosensor system (Pharmacia Biosensor AB, Uppsala, Sweden). All
experiments were performed at 25 °C with a constant flow rate of 10 µl/min. Synthetic peptides were directly coupled to a
carboxymethylated dextran matrix (CM5 sensor chip, Pharmacia Biosensor). Peptide 1 was coupled through its amino groups according to
the protocol provided by Pharmacia Biosensor. Peptides 2 and 3 were
immobilized through their unique C-terminal thiol group according to
the protocols provided by Pharmacia Biosensor and modified as follows.
Before peptide injection, excess of reactive carboxyl groups was
inactivated with 35 µl of 1 mM ethanolamine hydrochloride, pH 8.5. After peptide immobilization, excess of reactive
disulfide groups were neutralized with 25 µl of 1 M NaCl, 50 mM cysteine in 0.1 M formate, pH 4.3, and
noncovalently bound peptides removed by a wash with 20 µl of 50 mM HCl. The concentration of peptide used was adjusted to
obtain an equivalent level of immobilization (expressed in
fmol/mm2) calculated according to the ratio of 1,000 units/ng
of peptide immobilized/mm2 given by Pharmacia Biosensor.
Purified RyR, previously dialyzed overnight at 4 °C against a buffer
containing 10 mM HEPES, pH 7.4, and 150 mM NaCl
was injected in the same buffer containing different concentrations of
EGTA and CaCl2 to obtain the wanted values of
pCa.
Overlay Assays--
2 µg of purified skeletal RyR were
separated on 5-15% SDS-polyacrylamide gel electrophoresis and
transferred on an Immobilon sheet. The Immobilon sheet was then blocked
with 1% bovine serum albumin for 30 min at room temperature in buffer
A (150 mM NaCl, 1 mM EGTA, 0.1% T20, 10 mM HEPES, pH 7.4). Overlay was carried out with 50 nM of biotinylated peptide 2 for 2 h at room
temperature in presence of 1% bovine serum albumin in buffer A. At the
end of the incubation, the blot was washed 3 times for 5 min in buffer A. Peptide 2 binding proteins were revealed by chemiluminescent technique using peroxidase-conjugated anti-biotin monoclonal antibodies (Jackson ImmunoResearch Laboratories, Inc.).
Immunoprecipitation of SR Proteins Using Antibodies Directed
Against Triadin or RyR--
The interaction between ryanodine receptor
and triadin was first tested by co-immunoprecipitation experiments with
specific antibodies. Solubilized HSR proteins were immunoprecipitated
with antibodies directed against N-terminal (A-Nter) or C-terminal (A-Cter) domain of triadin or with antibodies directed against RyR, as
described under "Experimental Procedures." Immunoprecipitated proteins were then analyzed by Western blot (Fig.
1) with antibodies directed against
either RyR or triadin. Fig. 1 shows that immunoprecipitation by A-Nter
or A-Cter leads to the co-precipitation of RyR and triadin, as
indicated by the labeling of the immune complex by both anti-RyR and
A-Cter antibodies, whereas preimmune serum is unable to precipitate either of this two proteins. Conversely, immunoprecipitation with antibodies directed against RyR leads to the co-precipitation of RyR
and triadin as indicated by immunobloting of the precipitated proteins
with A-Cter and anti-RyR antibodies. These results confirm the
existence of a complex containing both RyR and triadin (30, 31,
39).
Effect of Anti-triadin Antibodies on the Functional Properties of
the RyR Ca2+ Channel--
To investigate the functional
role of the RyR-triadin interaction, we tested the effect of
anti-triadin antibodies on Ca2+ uptake and Ca2+
release from SR vesicles as well as on the RyR Ca2+ channel
behavior. Using proteolytic degradation techniques, we have previously
shown that the first 47 amino acids of triadin are protruding into the
cytoplasm, whereas the rest of the protein is localized within the SR
lumen (29). We therefore focused our study on the role of the
cytoplasmic domain of triadin in the regulation of Ca2+
release from SR and tested the effect of the A-Nter antibodies, directed against residues 2-17 of triadin, on Ca2+ release
from SR vesicles. SR vesicles, incubated in the presence or absence of
A-Nter antibodies, were actively loaded with Ca2+ and then
tested for Ca2+ release, as described under "Experimental
Procedures." As shown in Fig.
2A, representing the time
course of Ca2+ uptake by SR vesicles preincubated in the
absence (trace A) or presence (trace B) of A-Nter
antibodies, these antibodies produce no significant effect on the
active Ca2+ loading of the SR vesicles. Under the
conditions used, the loading level was 103.4 ± 14.0 (n = 6) and 97.3 ± 5.8 (n = 8)
nmol/mg for SR vesicles incubated in the absence or presence of A-Nter, respectively. In contrast, under the same conditions, incubation of the
SR vesicles with A-Nter antibodies induces a clear inhibition of the
Ca2+ release measured in the presence of caffeine (Fig.
2B, curves B and C compared with
curve A). The initial rate of Ca2+ release,
calculated from the slope of Ca2+ release curve at time 0, decreased from 288 nmol of Ca2+ mg
We then studied the effect of A-Nter antibodies on the intrinsic
properties of the RyR Ca2+ channel after incorporation of
HSR vesicles in planar lipid bilayer. Fig.
3 shows the single channel recording and
current integral obtained using Na+ as the current carrier.
In control conditions (pCa 5.5 and 1 mM ATP), we
observed a high conductance channel (490 pS) (Fig. 3, left
trace). In the cis chamber, the addition of Fab
fragment of the A-Nter induces a decrease of the normalized open
probability of the channel from 0.25 (control conditions) to 0.03 (right trace), corresponding to an inhibition of 73 ± 8% (n = 4) of the RyR current. Neither addition of
antigenic peptide alone nor that of A-Nter antibodies preincubated with
the peptide induces a change of Ca2+ channel activity (data
not shown). This channel was previously identified as the RyR
Ca2+ channel based on its sensitivity to Ca2+,
ryanodine, and ruthenium red (21). When purified RyR was incorporated into lipid bilayers, no effect of the A-Nter triadin antibodies on RyR
Ca2+ channel activity was observed (data not shown),
confirming the fact that the effect of A-Nter antibodies on RyR must
occur via triadin. These data strongly suggest that the inhibition of
the Ca2+ release from SR by A-Nter antibodies results from
the reduction of the RyR Ca2+ channel open probability by
these antibodies.
Molecular Interaction of RyR with the N-terminal Domain of
Triadin--
The effect of A-Nter antibodies on the RyR
Ca2+ channel properties described above could be due to the
modification of a direct interaction between RyR and the cytoplasmic
N-terminal region of triadin or an at-distance modification of the
interaction between another region of triadin and RyR. The existence of
a direct molecular interaction between RyR and the N-terminal region of
triadin was then addressed using surface plasmon resonance technique.
For these experiments, two peptides corresponding to residues 2-17 (peptide 1) and 18-46 (peptide 2) of triadin, respectively, were synthesized and immobilized to the dextran matrix coating the sensor
chip. The interaction of each peptide with purified RyR was then
monitored using the optical biosensor BIAcore. Fig.
4 depicts the amplitude of the binding
signal corresponding to the interaction of purified RyR with peptides 1 and 2 in the presence of 1 mM EGTA or 2 mM
Ca2+. Of these two peptides, only peptide 2 interacts with
purified RyR in the presence of EGTA but not in the presence of 2 mM Ca2+. No interaction of purified RyR with
peptide 1 was observed in the presence of EGTA or Ca2+.
Accessibility of immobilized peptide 1 was ensured by its reactivity with A-Nter antibodies (data not shown).
In the next set of experiments, we analyzed in more detail the
interaction of purified RyR with peptide 2 in the presence of 1 mM EGTA. Fig. 5, upper
trace, shows the sensorgrams representing the real time
interaction of peptide 2 with increasing concentrations of purified
RyR. Fig. 5, lower trace shows that the resonance unit
response corresponding to the binding of purified RyR on peptide 2 is
dose-dependent and approaches the saturation for concentrations of purified RyR close to 200 nM with an
apparent affinity of 27 ± 5 nM (n = 4). The interaction between the purified RyR and the immobilized
peptide 2 could be inhibited by preincubation of RyR with peptide 2 (data not shown). Nonspecific interaction between purified RyR and the
activated surface sensor was measured on either a surface coated with
peptide 3, unrelated to triadin (Fig. 5, curve E), or a
surface sensor without immobilized peptide. In both cases, the
nonspecific interaction was consistently found to represent less than
10% of the total binding signal.
However the surface plasmon resonance interaction signal described
above could reflect the interaction of triadin with RyR via another
protein present in the purified RyR preparation. To test this
hypothesis we performed overlay of biotinylated peptide 2 on purified
RyR. Fig. 6, lane 1, shows
that immunolabeling by anti-biotin antibodies of purified RyR
preparation overlaid with biotinylated peptide 2 leads to the labeling
of two bands corresponding to the high molecular weight protein RyR and
to a lower molecular mass peptide (approximately 58 kDa), respectively.
However labeling of the 58-kDa peptide was also observed when overlay
was performed in the absence of peptide 2 (Fig. 6, lane 2)
and is therefore likely due to a nonspecific labeling by the
anti-biotin antibodies themselves. These results clearly demonstrate
the direct molecular interaction between RyR and peptide 2 in presence
of 1 mM EGTA.
Therefore we investigated the effect of the free Ca2+
concentration on the interaction of RyR with peptide 2. Purified RyR, at a fixed concentration, was injected on the peptide-coated sensor surface in a buffer containing different free Ca2+
concentrations. Fig. 7 represents the
variation of the specific binding signal amplitude as a function of
[Ca2+] and shows that RyR-peptide 2 interaction is
optimal at low Ca2+ concentrations (below micromolar) and
is inhibited by increasing [Ca2+] with IC50
for Ca2+ in the range of 300 µM. These
results clearly indicate that purified RyR interacts directly with the
peptide corresponding to residues 18-46 of triadin, this interaction
being regulated by Ca2+.
Effect of Peptide 2 on the Functional Properties of the Purified
RyR Ca2+ Channel--
Fig. 8
shows the recording of channel activity of purified RyR incorporated
into lipid bilayers. As mentioned above, addition of A-Nter triadin
antibodies to purified RyR incorporated to lipid bilayer did not induce
any change in the RyR activity, indicating that the effect of these
antibodies on RyR occur via triadin. Therefore we tested the effect of
peptide 2 on the activity of the purified RyR incorporated into lipid
bilayer. In the presence of 1 mM ATP and 3 µM
free Ca2+ in the cis chamber, RyR was
consistently open as shown on Fig. 8 (control). The addition
of peptide 2 (100 nM final concentration) in the
cis chamber induces a decrease of the normalized open
probability of the channel from 0.19 to 0.04 corresponding to a 79%
inhibition of the current. These results demonstrate that the molecular
interaction of peptide 2 with purified RyR induces the inhibition of
the RyR channel activity.
In conclusion, several new aspects of the interaction of triadin and
RyR are described here. Our results represent the first evidence of a
direct interaction of the cytoplasmic domain of triadin with RyR.
Moreover, these results allow us to define a discrete domain restricted
to the residues 18-46 of this cytoplasmic portion of triadin as
responsible for the interaction with RyR. The interaction of the
cytoplasmic domain of triadin with RyR is inhibited at millimolar
[Ca2+]. We show that the cytoplasmic domain of triadin
plays a functional role in the regulation of the Ca2+
release from SR via the control of the RyR Ca2+ channel
behavior. Indeed, antibodies directed against the cytoplasmic region of
triadin induce both an inhibition of Ca2+ release from SR
and a decrease of the open probability of RyR Ca2+ channel.
Moreover, peptide 2 representing the domain of triadin directly
involved in the interaction with the RyR can induce in vitro
the inhibition of the RyR channel activity. These results clearly
demonstrate that triadin-RyR interaction directly modulates the
intrinsic RyR Ca2+ channel properties and are in agreement
with previous works (32, 33) suggesting that triadin is involved in the
control of Ca2+ flux from SR.
Recently, Ohkura et al. (36) have shown that addition of
purified skeletal triadin to the cytoplasmic side of purified RyR incorporated in lipid bilayer induces a complete inhibition of RyR
channel activity, whereas addition of triadin to the luminal side does
not produce any change in the RyR activity. These authors propose that
this regulation of RyR by triadin involves a cytoplasmic domain of
triadin. According to our results, the cytoplasmic domain of triadin
encompassing residues 18-46 could be a good candidate to mediate this
interaction. Therefore we propose that the binding of the A-Nter to its
epitope, which is located within the first 17 residues of triadin,
stabilizes the interaction of a specific site, located between residues
18 and 46 of triadin, with RyR, leading to the stabilization of the
closed state of the RyR Ca2+ channel. The involvement of
triadin in the control of RyR via the cytoplasmic side also agrees with
the results obtained by Liu and Pessah (33) showing the effect of
cytoplasmic modulators on both triadin and RyR. However, this
interaction of triadin with the RyR has to be strictly regulated.
Interestingly, Guo and Campbell (31) have shown that the luminal domain
of triadin is able to interact with both RyR and calsequestrin and have
proposed that triadin could be the link between these two proteins.
Therefore, according to the results presented here, it appears that
triadin not only could mediate the control of the RyR Ca2+
channel activity by luminal Ca2+ but also participate in
the regulation of the RyR channel activity by cytoplasmic factors.
Moreover, the luminal part of triadin could play a role in the
regulation of the inhibitory effect of the cytoplasmic domain,
providing a direct link between the luminal Ca2+
concentration and the RyR activity. The strict dependence on free
cytoplasmic Ca2+ concentration of the interaction of the
cytoplasmic domain of triadin with RyR, described above, likely
explains why Guo and Campbell (31) did not see any interaction of RyR
with the fusion protein corresponding to the cytoplasmic domain of
triadin, because their experiments were performed in the presence of
mM Ca2+. Interestingly the RyR-triadin
interaction highlighted in the present work is shown to be inhibited by
Ca2+ in a range of concentrations in which Ca2+
has previously been shown to control Ca2+ release from SR
as well as ryanodine binding on RyR and therefore the functional state
of RyR (7, 35). This effect of Ca2+ on the RyR-triadin
interaction suggests that the interaction of the cytoplasmic domain of
triadin with RyR depends on the RyR conformational state and vice
versa. Moreover, RyR·triadin complex is stabilized in the
presence of Ca2+ concentrations corresponding to the
cytoplasmic Ca2+ level of the resting cell, and strongly
disfavored in the presence of Ca2+ concentrations
corresponding to the [Ca2+] locally reached when RyR
Ca2+ channels open. Therefore, RyR-triadin interaction, by
sensing the [Ca2+] at the RyR channel mouth, could
represent in vivo an important step of control of the RyR
Ca2+ channel opening and closing by cytoplasmic
Ca2+ level. The identification of the region of the
ryanodine receptor involved in the interaction with the cytoplasmic
domain of triadin will help to understand the process of cross-talk
between triadin and RyR. In cardiac SR, the ryanodine receptor has been
shown to also interact with an other integral membrane protein called junctin also present in skeletal muscle SR (25, 34). Although junctin
and triadin show some similarities (25), the primary sequence of their
cytoplasmic domain strongly differs, suggesting that they may have a
different function, whereas their luminal domain sharing some
association motifs is involved in the interaction with RyR and
calsequestrin. Comparison of the effect of cytoplasmic domain of
triadin and junctin could help to understand the respective role of
these proteins.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
arsenazo III
signal/
[Ca2+] coefficient from a calibration curve.
The concentration of the contaminant Ca2+ brought by HSR
vesicles and buffer was calculated to be 20 µM.
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
View larger version (33K):
[in a new window]
Fig. 1.
Immunoprecipitation of solubilized HSR
proteins with antibodies directed against triadin or ryanodine
receptor. Solubilized HSR proteins were immunoprecipitated as
described under "Experimental Procedures" with A-Nter antibodies,
preimmune serum, A-Cter antibodies, or anti-RyR antibodies. The immune
complexes formed were analyzed in Western blot with anti-RyR or
anti-triadin (A-Cter) antibodies. The first lane (HSR)
corresponds to Western blot analysis of HSR proteins revealed by
anti-RyR antibodies or anti-triadin antibodies.
1
s
1 protein, trace A (no antibodies), to 96 and
37 nmol of Ca2+ mg
1 s
1 protein,
trace B (proteins/A-Nter = 20) and trace C
(proteins/A-Nter = 10). No significant change of Ca2+
release rate was observed when SR vesicles were incubated with the
peptide alone (data not shown) or with A-Nter antibodies pre-incubated with the corresponding peptide (curve D). These results
clearly demonstrate that antibodies directed against the cytoplasmic
domain of triadin inhibit Ca2+ release from SR vesicles.
Therefore, modifying triadin can induce a modification of RyR function.
However this effect of A-Nter antibodies could result from modification
by the antibodies of either the RyR Ca2+ channel
properties, or any other step of the Ca2+ release
process.
View larger version (14K):
[in a new window]
Fig. 2.
Effect of A-Nter antibodies on
Ca2+ uptake (A) and Ca2+
release (B) from SR vesicles. A,
Ca2+ uptake. HSR vesicles incubated in the absence of
antibodies (curve a) or presence of A-Nter antibodies
(curve b) (protein/Ab = 10) were actively loaded in the
presence of ATP-Mg. Each curve represents the average of four different
experiments. The amount of Ca2+ loaded, determined as
described under "Experimental Procedures" was 103.4 ± 14.0 (mean ± S.D., n = 6) and 97.3 ± 5.8 (mean ± S.D., n = 8) nmol/mg of SR vesicles
incubated in the absence or presence of A-Nter antibodies
(protein/Ab = 10 mg/mg), respectively. B, time course
of Ca2+ release. HSR vesicles preincubated in the absence
of antibodies (curve A), in presence of A-Nter antibodies
(curves B (protein/Ab = 20 mg/mg) and C
(protein/Ab = 10 mg/mg)), or in the presence of A-Nter antibodies
(protein/Ab = 20 mg/mg) preincubated with corresponding peptide
(curve D) (Ab/peptide = 6 mg/mg) were actively loaded
with Ca2+ for 15 min. Ca2+ release was then
induced in presence of caffeine as described under "Experimental
Procedures." Data represent the average of 10 to 15 traces (each
representing 4,000 data points) and are representative of at least
three experiments.
View larger version (32K):
[in a new window]
Fig. 3.
Effect of A-Nter antibodies on skeletal RyR
Ca2+ channel incorporated into lipid bilayers. HSR
vesicles were fused with lipid bilayer and single channel recording and
current integral versus time were measured as described
under "Experimental Procedures." Current integral values are 1429 pA·ms before addition of antibodies (control), and 178 pA·ms after addition of Fab fragment of A-Nter antibodies (1/110).
Horizontal arrows indicate the closed state of the channel.
This experiment is representative of four experiments.
View larger version (12K):
[in a new window]
Fig. 4.
Interaction of purified RyR with peptide 1 and peptide 2. Peptides 1 and 2 corresponding to residues 2-17
and 18-46 of cytoplasmic domain of triadin, respectively, were
immobilized on the sensor chip surface as described under
"Experimental Procedures." 1.4 and 1 µg of purified RyR were
injected on immobilized peptides 1 (169 fmol/mm2) and 2 (58-184 fmol/mm2), respectively, in presence of 1 mM EGTA or 2 mM Ca2+ as described
under "Experimental Procedures." To facilitate the comparison
between the results obtained with peptides 1 and 2, RyR interaction
signal was normalized for a peptide immobilization value of 169 fmol/mm2. Data are expressed as mean ± S.D. of total
purified RyR binding.
View larger version (15K):
[in a new window]
Fig. 5.
Interaction of purified RyR with peptide 2 in
absence of Ca2+. Purified RyR was injected at various
concentrations on the peptide 2 immobilized (142 fmol/mm2)
on the sensor chip surface (upper trace). Curve A, 200 ng of
RyR; curve B, 500 ng of RyR; curve C, 1 µg of
RyR; curve D, 5 µg of RyR. Curve E represents
the binding of RyR (500 ng) with peptide 3. Lower trace,
amplitude of the specific binding signal (total nonspecific)
corresponding to the interaction of purified RyR with peptide 2 as a
function of [RyR]. The curve represents the best fit of
the data by the equation y = a(1 exp(
bx)). This experiment is representative of four
different sets of experiments. The calculated apparent affinity of RyR
for peptide 2 is 27 ± 5 nM (mean ± S.D.,
n = 4).
View larger version (31K):
[in a new window]
Fig. 6.
Biotinylated peptide 2 overlay of purified
RyR. 2 µg of purified RyR preparation were separated on 5-15%
SDS-polyacrylamide gel electrophoresis and blotted onto Immobilon
sheets as described under "Experimental Procedures." Ligand overlay
was carried out for 2 h at room temperature in a buffer containing
150 mM NaCl, 1 mM EGTA, 0.1% T20, 1% bovine
serum albumin, 10 mM HEPES, pH 7.4, in the presence
(lane 1) or the absence (lane 2) of 50 nM biotinylated peptide 2 of triadin. Peptide 2-binding
proteins were revealed with monoclonal anti-biotin antibodies.
View larger version (10K):
[in a new window]
Fig. 7.
Effect of Ca2+ on the interaction
of purified RyR with peptide 2. Peptide 2 was immobilized on the
sensor chip surface as described under "Experimental Procedures"
and its interaction with purified RyR (1.5 µg) measured in a buffer
containing 10 mM HEPES, 150 mM NaCl, 1 mM EGTA, and various [Ca2+] to obtain various
pCa values. Specific binding values were normalized to
percentage of the maximal binding value measured at pCa 9. The curve represents the best fit of the data by the equation
y = a(b/(b + e( 2.3x))), providing an IC50 value
for Ca2+ of 300 µM.
View larger version (33K):
[in a new window]
Fig. 8.
Effect of peptide 2 on purified RyR
Ca2+ channel incorporated into lipid bilayers.
Purified RyR was fused with lipid bilayer and single channel recording
and current integral versus time were measured as described
under "Experimental Procedures." Current integral values are 1138 pA·ms before the addition of peptide 2 (control) and 215 pA·ms after addition of peptide 2 (100 nM final
concentration). Horizontal arrows indicate the closed state
of the channel. This experiment is representative of four
experiments.
![]() |
FOOTNOTES |
---|
* This work was supported by Grants from Institut National de la Santé et de la Recherche Médicale (CJF 9709) and Association Française contre les Myopathies.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Present address: Dept. of Physiology and Medicine, UCLA, 675 Circle Dr. South, MRL 3645, Los Angeles, CA 90095.
To whom correspondence should be addressed. Tel.:
33-4-76-88-46-69; Fax: 33-4-76-88-54-87; E-mail: mronjat{at}cea.fr.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: SR, sarcoplasmic reticulum; HSR, heavy SR; RyR, ryanodine receptor; DHPR, dihydropyridines receptor; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; MES, 4-morpholinoethanesulfonic acid; Ab, antibody.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|